Clinical TrialMay 21, 2026, 08:02 PM
Ascentage Pharma to Present Positive Clinical Data for 3 Candidates at ASCO 2026
AI Summary
Ascentage Pharma announced that six abstracts from its clinical studies, featuring three lead drug candidates (olverembatinib, lisaftoclax, and alrizomadlin), have been selected for presentation at the 2026 ASCO Annual Meeting. Three studies will be rapid oral presentations and three will be poster presentations. The abstracts report positive efficacy and safety data from ongoing studies, including high response rates for olverembatinib in CML and preliminary antitumor activity for alrizomadlin alone or in combination with lisaftoclax in pediatric sarcomas. Updates on two global Phase 3 registrational studies (POLARIS-2 for olverembatinib and GLORA for lisaftoclax) will also be presented.
Key Highlights
- Olverembatinib combined with blinatumomab achieved CR in 4 of 5 MRD+ patients and MRD negativity in 2 patients with CML-LBP/Ph+ BCP-ALL.
- Olverembatinib as second-line therapy in CP-CML showed 91.3% complete cytogenetic response (CCyR) and 60.9% major molecular response (MMR) at cycle 24.
- For CP-CML patients failing first-line TKIs, olverembatinib achieved 81.3% CCyR and 50% MMR.
- Alrizomadlin monotherapy achieved complete response in one pediatric rhabdomyosarcoma patient.
- Alrizomadlin combined with lisaftoclax in pediatric solid tumors showed an objective response rate (ORR) of 30% and disease control rate (DCR) of 80%.
- Olverembatinib in SDH-deficient GIST resulted in 23.1% partial response (PR) and median progression-free survival (PFS) of 25.7 months.
- Global Phase 3 registrational trials, POLARIS-2 for olverembatinib in CML and GLORA for lisaftoclax in CLL/SLL, are in progress.
- GLORA trial aims to enroll approximately 440 patients across 126 centers in 18 countries.
Price Impact
More from AAPG